| Literature DB >> 20632888 |
Jiang Wu1, Wei Li, Hua-Qing Wang, Jiang-Ting Chen, Min Lv, Ji-Chen Zhou, Xiao-Feng Liang, Han-Hua Fang, Yan Liu, Li-Ying Liu, Xu Wang, Wu-Li Zhang, Xiao-Mei Zhang, Li-Fei Song, Yuan-Zheng Qiu, Chang-Gui Li, Jun-Zhi Wang, Yu Wang, Wei-Dong Yin.
Abstract
A double-blind, randomized, controlled trial involving 706 adults was conducted to evaluate the immunogenicity and safety of different dosages of whole-virion or split-virion H1N1 influenza vaccines with or without aluminum adjuvant. A rapid and strong immune response was induced at day 14 after the first injection. The seroprotection rates ranged from 72.7% (95% confidence interval [CI], 62.7%-81.1%) for 5-microg whole-virion aluminum formulation to 97.0% (95% CI, 90.9%-99.7%) for 30-microg split-virion nonaluminum formulation. All formulations were well tolerated. The incidences of mild, moderate, and severe reactions were 71 (10.1%), 15 (2.1%), and 1 (0.1%) of 706 reactions, respectively. The 15-microg split-virion formulation had the best immunogenicity and safety.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20632888 DOI： 10.1086/655226
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226